IRIS - Res&Arch Institutional Research Information System - Research & Archive

GAETANI, LORENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.881
AS - Asia 1.520
EU - Europa 1.169
SA - Sud America 232
AF - Africa 38
OC - Oceania 7
Totale 4.847
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.837
SG - Singapore 716
IT - Italia 287
HK - Hong Kong 265
CN - Cina 256
IE - Irlanda 221
BR - Brasile 199
RU - Federazione Russa 129
DE - Germania 118
KR - Corea 76
SE - Svezia 72
FI - Finlandia 70
VN - Vietnam 67
GB - Regno Unito 50
IN - India 31
NL - Olanda 30
FR - Francia 28
UA - Ucraina 23
JP - Giappone 21
CA - Canada 19
RO - Romania 19
BE - Belgio 18
PL - Polonia 18
AT - Austria 17
CZ - Repubblica Ceca 17
BD - Bangladesh 15
ZA - Sudafrica 13
MX - Messico 12
TR - Turchia 12
AR - Argentina 11
UZ - Uzbekistan 11
HR - Croazia 9
ES - Italia 8
GR - Grecia 8
ID - Indonesia 8
IQ - Iraq 8
CO - Colombia 6
EC - Ecuador 6
SA - Arabia Saudita 6
LT - Lituania 5
MA - Marocco 5
NZ - Nuova Zelanda 5
AE - Emirati Arabi Uniti 4
CH - Svizzera 4
EG - Egitto 4
JM - Giamaica 4
PY - Paraguay 4
TN - Tunisia 4
DK - Danimarca 3
GE - Georgia 3
KZ - Kazakistan 3
LB - Libano 3
PK - Pakistan 3
PT - Portogallo 3
AZ - Azerbaigian 2
GM - Gambi 2
GY - Guiana 2
IR - Iran 2
IS - Islanda 2
KE - Kenya 2
NI - Nicaragua 2
NO - Norvegia 2
PA - Panama 2
SD - Sudan 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
VE - Venezuela 2
AF - Afghanistan, Repubblica islamica di 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BY - Bielorussia 1
CL - Cile 1
CM - Camerun 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
ET - Etiopia 1
HN - Honduras 1
HT - Haiti 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NP - Nepal 1
PF - Polinesia Francese 1
PG - Papua Nuova Guinea 1
PS - Palestinian Territory 1
RE - Reunion 1
SI - Slovenia 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
ZM - Zambia 1
Totale 4.847
Salva come PNG Salva come JPEG
Città #
Singapore 480
Chandler 257
Hong Kong 256
Dublin 221
Ashburn 146
Perugia 141
Boardman 123
Santa Clara 83
Seoul 76
Los Angeles 71
Munich 69
San Mateo 68
Beijing 66
Altamura 59
Moscow 56
Des Moines 42
Medford 40
New York 40
Princeton 40
Andover 39
Lawrence 39
Ann Arbor 38
Wilmington 35
Piscataway 34
Helsinki 30
Turku 26
Redmond 24
Denver 20
Ho Chi Minh City 20
Boston 19
São Paulo 19
Redwood City 18
Amsterdam 17
Brooklyn 17
Chennai 17
Houston 17
The Dalles 17
Tokyo 17
Hanoi 15
Brussels 14
Nuremberg 14
Phoenix 14
Rome 14
Falls Church 13
Vienna 13
Brno 12
Dallas 12
Stockholm 12
Warsaw 12
Manchester 11
Chicago 10
Johannesburg 10
Poplar 10
Timisoara 10
Frankfurt am Main 9
London 9
Seattle 9
Columbus 8
Hefei 8
Milan 8
Montreal 8
Orem 8
San Francisco 8
Tashkent 8
Zagreb 8
Atlanta 7
Fairfield 7
Lappeenranta 7
Rio de Janeiro 7
Bucharest 6
Falkenstein 6
Norwalk 6
Saint Petersburg 6
Secaucus 6
Ankara 5
Auckland 5
Campinas 5
Dong Ket 5
Guangzhou 5
Woodbridge 5
Belo Horizonte 4
Haiphong 4
Mexico City 4
Ninh Bình 4
Porto Alegre 4
Shenzhen 4
Athens 3
Biên Hòa 3
Charlotte 3
Giza 3
Goiânia 3
Groningen 3
Izmir 3
Kingston 3
Milwaukee 3
Mumbai 3
New Delhi 3
Newark 3
Olomouc 3
Pittsburgh 3
Totale 3.238
Salva come PNG Salva come JPEG
Nome #
CSF and blood biomarkers for Parkinson's disease 170
Synaptic plasticity and experimental autoimmune encephalomyelitis: implications for multiple sclerosis 127
Positive allosteric modulation of indoleamine 2,3-dioxygenase 1 restrains neuroinflammation 125
Microglial activation and the nitric oxide/cGMP/PKG pathway underlie enhanced neuronal vulnerability to mitochondrial dysfunction in experimental multiple sclerosis 121
Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis 118
CSF and Blood Biomarkers in Neuroinflammatory and Neurodegenerative Diseases: Implications for Treatment 101
A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation 100
Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis 99
2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes 97
Visual pathway involvement in multiple sclerosis: Look straight in the eyes 94
Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis 93
Extracranial Venous Drainage Pattern in Multiple Sclerosis and Healthy Controls: Application of the 2011 Diagnostic Criteria for Chronic Cerebrospinal Venous Insufficiency 89
Lower urinary tract symptoms and urodynamic dysfunction in clinically isolated syndromes suggestive of multiple sclerosis 88
Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers 83
Psychiatric symptoms in multiple sclerosis: a biological perspective on synaptic and network dysfunction 82
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes 78
Host and Microbial Tryptophan Metabolic Profiling in Multiple Sclerosis 74
Retinopathy during interferon-β treatment for multiple sclerosis: case report and review of the literature 74
Cerebrospinal fluid levels of proenkephalin and prodynorphin are differentially altered in Huntington's and Parkinson's disease 73
CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment 71
Insights into the pathophysiology of psychiatric symptoms in central nervous system disorders: Implications for early and differential diagnosis 69
Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer's disease 68
High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline 66
A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis 65
Headache and immunological/autoimmune disorders: a comprehensive review of available epidemiological evidence with insights on potential underlying mechanisms 65
Recurrent hyperCKemia with normal muscle biopsy in a pediatric patient with neuromyelitis optica 64
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis 64
Molecular profiling in Parkinsonian syndromes: CSF biomarkers 64
The Challenge of Disease-Modifying Therapies in Parkinson's Disease: Role of CSF Biomarkers. 62
Tracing Neurological Diseases in the Presymptomatic Phase: Insights From Neurofilament Light Chain 62
Synaptic dysfunction in multiple sclerosis: A red thread from inflammation to network disconnection 62
Neurofilament light chain as a biomarker in neurological disorders 61
Cerebrospinal fluid β-synuclein as a synaptic biomarker for preclinical Alzheimer's disease 61
Biomarker-Based Prediction of Parkinson Disease: Time for a Shift in Neurologists' Attitude Toward Neurodegenerative Diseases 58
Serum neurofilament light chain as a preclinical marker of neurodegeneration 58
Finding a way to preserve mitochondria: New pathogenic pathways in experimental multiple sclerosis 58
High performance liquid chromatography determination of L-glutamate, L-glutamine and glycine content in brain, cerebrospinal fluid and blood serum of patients affected by Alzheimer's disease 58
Neuroinflammation and Alzheimer's Disease: A Machine Learning Approach to CSF Proteomics 58
The no evidence of disease activity (NEDA) concept in MS: impact of spinal cord MRI 58
Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease 57
Infliximab monotherapy for neuro-Behçet's disease: a case report 57
Multiple sclerosis and chronic progressive external ophthalmoplegia associated with a large scale mitochondrial DNA single deletion 57
Blood biomarkers may distinguish among dementia disorders 56
α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward 56
Potential diagnostic value of CSF metabolism-related proteins across the Alzheimer's disease continuum 55
Author Response: NfL as Analogue of C-Reactive Protein in Neurologic Diseases: Instructions for Use 55
Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: Disease staging by NF-L, p-tau181, and GFAP 54
Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study 54
Impact of post-contrast MRI in the definition of active multiple sclerosis 53
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis? 53
Investigating alpha-synuclein co-pathology in Alzheimer's disease by means of cerebrospinal fluid alpha-synuclein seed amplification assay 52
A blood test for Alzheimer's disease: a step forward 52
Phosphatidylethanolamine Binding Protein 1 (PEBP1) in Alzheimer's Disease: ELISA Development and Clinical Validation 51
Association between Neuropsychological Performance and CSF Profile in Subjective Cognitive Decline: Towards the Diagnosis of Preclinical AD 50
Cerebrospinal fluid interferon-γ and development of depression in multiple sclerosis 50
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease 50
Lower urinary tract symptoms and urodynamic dysfunctions in clinically isolated syndromes suggestive of multiple sclerosis. 50
Intrathecal B cell activation and memory impairment in multiple sclerosis 49
Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer's Disease and Other Neurological Disorders 49
CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease 48
Post-contrast MRI in multiple sclerosis: Towards a judicious use of gadolinium-based contrast agents 48
Clinical correlates of state and trait anxiety in multiple sclerosis 48
Alpha and Beta Synucleins: From Pathophysiology to Clinical Application as Biomarkers 48
CSF synaptic biomarkers and cognitive impairment in multiple sclerosis 47
Immunoassay detection of multiphosphorylated tau proteoforms as cerebrospinal fluid and plasma Alzheimer’s disease biomarkers 47
LRRK2 Quantification in Cerebrospinal Fluid of Patients with Parkinson's Disease and Atypical Parkinsonian Syndromes 45
CSF and plasma Aβ42/40 across Alzheimer's disease continuum: comparison of two ultrasensitive Simoa® assays targeting distinct amyloid regions 43
Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias 42
Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer's disease 41
The Immune Signature of CSF in Multiple Sclerosis with and without Oligoclonal Bands: A Machine Learning Approach to Proximity Extension Assay Analysis 41
Fully automated measurement of plasma Aβ42/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer's disease continuum in two independent cohorts 41
CSF neurosecretory proteins VGF and neuroserpin in patients with Alzheimer's and Lewy body diseases 40
CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective 35
SARS-CoV-2 vaccines tolerability: A perspective by people with multiple sclerosis 32
Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis – a multicentre study 30
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment 30
Hippocampal neuroplasticity and inflammation: Relevance for multiple sclerosis 29
Research advancement in fluid biomarkers for Parkinson's disease 29
Fluid biomarkers in multiple sclerosis: from current to future applications 25
Totale 4.987
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.018
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.018
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202173 0 0 0 0 0 17 7 20 11 5 6 7
2021/2022380 3 49 12 12 26 10 5 93 17 46 61 46
2022/2023858 45 184 15 68 62 104 4 38 302 1 26 9
2023/2024511 24 54 15 11 7 2 97 20 68 26 80 107
2024/20251.392 13 108 69 75 122 103 95 139 239 85 220 124
2025/20261.500 205 239 128 412 430 86 0 0 0 0 0 0
Totale 4.987